Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...
SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Cutaneous Melanoma (Version 1.2026), recognizing Merlin ...
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...
ROCHESTER, Minn. — A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes — a finding that could ...
TAMPA, Fla. (Oct. 22, 2025) — A large multicenter clinical trial published in JAMA Surgery shows that a gene expression profile–based test can reliably identify melanoma patients who have a low risk ...
The primary way to diagnose lymphoma involves a lymph node biopsy. However, doctors may utilize several other diagnostic procedures depending on a person’s lymphoma. Doctors can use blood tests, ...
Verywell Health on MSN
The LDH test for melanoma and detection of metastasis
Medically reviewed by Steffini Stalos, DO Key Takeaways The LDH test helps doctors stage and monitor advanced melanoma.High ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results